OBJECTIVE: HIV-related renal dysfunction is associated with high mortality. Data on the prevalence of renal dysfunction among HIV-infected outpatients starting antiretroviral therapy (ART) in sub-Saharan Africa are limited. Recent recommendations to include the nephrotoxic drug tenofovir in first-line ART regimens make clarification of this issue urgent. METHODS: We screened for renal dysfunction by measuring serum creatinine, proteinuria, and microalbuminuria in HIV-positive outpatients initiating ART in Mwanza, Tanzania. We excluded patients with pre-existing renal disease, hypertension, diabetes, or hepatitis C virus co-infection. Estimated glomerular filtration rates (eGFRs) were calculated by Cockroft-Gault and Modification of Diet in Renal Disease equations. RESULTS: Only 129 (36%) of 355 enrolled patients had normal eGFRs (grade 0 or 1) above 90 ml/min per 1.73 m. Grade 2 renal dysfunction (eGFR between 60 and 89 ml/min per 1.73 m) was present in 137 patients (38.6%), and 87 patients (25%) had grade 3 dysfunction (eGFR between 30 and 59 ml/min per 1.73 m). Microalbuminuria and proteinuria were detected in 72 and 36% of patients, respectively. Factors predictive of renal dysfunction in multivariate analysis included female sex [odds ratio (OR) 3.0, 95% confidence interval (1.8-5.1), P < 0.0001], BMI less than 18.5 [OR 2.3 (1.3-4.1), P = 0.004], CD4 T-cell count below 200 cells/μl [OR 2.3 (1.1-4.8), P = 0.04], and WHO clinical stage II or above [OR 1.6 (1.2-2.3), P = 0.001]. CONCLUSION: Renal dysfunction was highly prevalent in this population of HIV-positive outpatients initiating first ART in Tanzania. This highlights the critical and underappreciated need to monitor renal function in HIV-positive patients in sub-Saharan Africa, particularly given the increasing use of tenofovir in first-line ART.
OBJECTIVE: HIV-related renal dysfunction is associated with high mortality. Data on the prevalence of renal dysfunction among HIV-infected outpatients starting antiretroviral therapy (ART) in sub-Saharan Africa are limited. Recent recommendations to include the nephrotoxic drug tenofovir in first-line ART regimens make clarification of this issue urgent. METHODS: We screened for renal dysfunction by measuring serum creatinine, proteinuria, and microalbuminuria in HIV-positive outpatients initiating ART in Mwanza, Tanzania. We excluded patients with pre-existing renal disease, hypertension, diabetes, or hepatitis C virus co-infection. Estimated glomerular filtration rates (eGFRs) were calculated by Cockroft-Gault and Modification of Diet in Renal Disease equations. RESULTS: Only 129 (36%) of 355 enrolled patients had normal eGFRs (grade 0 or 1) above 90 ml/min per 1.73 m. Grade 2 renal dysfunction (eGFR between 60 and 89 ml/min per 1.73 m) was present in 137 patients (38.6%), and 87 patients (25%) had grade 3 dysfunction (eGFR between 30 and 59 ml/min per 1.73 m). Microalbuminuria and proteinuria were detected in 72 and 36% of patients, respectively. Factors predictive of renal dysfunction in multivariate analysis included female sex [odds ratio (OR) 3.0, 95% confidence interval (1.8-5.1), P < 0.0001], BMI less than 18.5 [OR 2.3 (1.3-4.1), P = 0.004], CD4 T-cell count below 200 cells/μl [OR 2.3 (1.1-4.8), P = 0.04], and WHO clinical stage II or above [OR 1.6 (1.2-2.3), P = 0.001]. CONCLUSION:Renal dysfunction was highly prevalent in this population of HIV-positive outpatients initiating first ART in Tanzania. This highlights the critical and underappreciated need to monitor renal function in HIV-positive patients in sub-Saharan Africa, particularly given the increasing use of tenofovir in first-line ART.
Authors: Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech Journal: Clin Infect Dis Date: 2005-04-22 Impact factor: 9.079
Authors: Lytt I Gardner; Scott D Holmberg; John M Williamson; Lynda A Szczech; Charles C J Carpenter; Anne M Rompalo; Paula Schuman; Robert S Klein Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Christina M Wyatt; Donald R Hoover; Qiuhu Shi; Eric Seaberg; Catherine Wei; Phyllis C Tien; Roksana Karim; Jason Lazar; Mary A Young; Mardge H Cohen; Paul E Klotman; Kathryn Anastos Journal: J Acquir Immune Defic Syndr Date: 2010-09 Impact factor: 3.731
Authors: Andrew Reid; Wolfgang Stöhr; A Sarah Walker; Ian G Williams; Cissy Kityo; Peter Hughes; Andrew Kambugu; Charles F Gilks; Peter Mugyenyi; Paula Munderi; James Hakim; Diana M Gibb Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: Kara Wools-Kaloustian; Samir K Gupta; Eva Muloma; Willis Owino-Ong'or; John Sidle; Ryan W Aubrey; Jianzhao Shen; Kirwa Kipruto; Beth E Zwickl; Mitchell Goldman Journal: Nephrol Dial Transplant Date: 2007-08 Impact factor: 5.992
Authors: Lloyd B Mulenga; Gina Kruse; Shabir Lakhi; Ronald A Cantrell; Stewart E Reid; Isaac Zulu; Elizabeth M Stringer; Zipporah Krishnasami; Alwyn Mwinga; Michael S Saag; Jeffrey S A Stringer; Benjamin H Chi Journal: AIDS Date: 2008-09-12 Impact factor: 4.177
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Wolfgang Stöhr; A Sarah Walker; Paula Munderi; Stefano Tugume; Charles F Gilks; Janet H Darbyshire; James Hakim Journal: Antivir Ther Date: 2008
Authors: Carlos Fritzsche; Jens Rudolph; Barbara Huenten-Kirsch; Christoph J Hemmer; Robert Tekoh; Pius B Kuwoh; Aenne Glass; Emil C Reisinger Journal: Am J Trop Med Hyg Date: 2017-11 Impact factor: 2.345
Authors: Hadas Zachor; Rhoderick Machekano; Michelle M Estrella; Peter J Veldkamp; Michele D Zeier; Olalekan A Uthman; Jantjie J Taljaard; Mohammed R Moosa; Jean B Nachega Journal: AIDS Date: 2016-05-15 Impact factor: 4.177